Continuous Renal Replacement Therapy (CRRT) clinical trials at UCLA
1 in progress, 0 open to eligible people
Prismocitrate 18 in Patients Receiving CRRT
Sorry, not currently recruiting here
Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit. The objectives of this study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or continuous venovenous hemofiltration (CVVH) and 2) to observe that the PrisMax System allows for implementation of regional citrate anticoagulation (RCA) (citrate and calcium dosing) during CRRT with Prismocitrate 18 and intended prescription. The study period of the patient's CRRT will be up to 10 days.
Los Angeles, California and other locations
Our lead scientists for Continuous Renal Replacement Therapy (CRRT) research studies include Mrinalini Sarkar, MD.
Last updated: